Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction
Tóm tắt
Novel oral anticoagulation (NOAC) has been introduced in recent years, but data on use in atrial fibrillation (AF) in primary care setting is scarce. In Germany, General Practitioners are free to choose type of oral anticoagulation (OAC) in AF. Our aim was to explore changes in prescription-rates of OAC in German primary care before and after introduction of NOAC on the market. Data of a representative morbidity registration project in primary care in Germany (CONTENT) were analysed. Patients with AF in 2011 or 2014 were included (before and after broad market authorization of NOAC, respectively). We defined three independent groups: patients from 2011 without follow-up (group A), patients from 2014 but without previous record in 2011 (group B) and patients with AF and records in 2011 and 2014 (group C). 2642 patients were included. Group A (n = 804) and B (n = 755) were comparable regarding patient characteristics. 87.3% of group A and 84.8% of group B had CHA2DS2-VASc-Score ≥ 2, indicating a need for oral anticoagulation (OAC). Prescription of OAC increased from 23.1% (n = 186) to 42.8% (n = 323, p < .01) with stable use of vitamin-k-antagonist (22.6–24.9%). NOAC increased from 0.6 to 19.2% (p < .01). Monotherapy with Acetylsalicylic acid (ASA) decreased from 15.3% (n = 123) to 8.2% (n = 62, p < .01). In group C (n = 1083), OAC increased from 35.3 to 55.4% (p < .01), with stable prescription rate of vitamin-k-antagonist (34.4–35.7%). NOAC increased from 0.9 to 21.5% (p < .01). In summary, our study showed a significant increase of OAC over time, which is fostered by the use of NOAC but with a stable rate of VKA and a sharp decrease of ASA. Patients on VKA are rarely switched to NOAC, but new patients with AF are more likely to receive NOAC.
Tài liệu tham khảo
Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes. 2012;5:85–93.
Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham heart study: a cohort study. Lancet. 2015;386:154–62.
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129:837–47.
Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–53.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983–8.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)developed with the special contribution of the European heart rhythm association (EHRA) of the ESCEndorsed by the European stroke organisation (ESO). Eur Heart J. 2016;37(38):2893-962. PMID: 27567408.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199–267.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.
Deutsche Gesellschaft fürAllgemeinmedizin und Familienmedizin. New oral anticoagulants, AWMF-Reg. 053/031. 2013, updated 2017 http://www.awmf.org/fileadmin/user_upload/Leitlinien/053_D_Ges_fuer_Allgemeinmedizin_und_Familienmedizin/053-031ke_S1_Antikoagulantien_NOAK_2017-01.pdf. Accessed June 5th 2018.
Mueller S, Pfannkuche M, Breithardt G, Bauersachs R, Maywald U, Kohlmann T, et al. The quality of oral anticoagulation in general practice in patients with atrial fibrillation. Eur J Intern Med. 2014;25:247–54.
Ulrich LR, Mergenthal K, Petersen JJ, Roehl I, Rauck S, Kemperdick B, et al. Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial. BMC Fam Pract. 2014;15:170.
Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18:1150–7.
Haeusler KG, Gerth A, Limbourg T, Tebbe U, Oeff M, Wegscheider K, et al. Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany - results from the German AFNET registry. BMC Neurol. 2015;15:129.
Robson J, Dostal I, Mathur R, Sohanpal R, Hull S, Antoniou S, et al. Improving anticoagulation in atrial fibrillation: observational study in three primary care trusts. Br J Gen Pract. 2014;64:e275–81.
Drug Commission of the Germal Medical Association. https://www.akdae.de/Arzneimitteltherapie/NA/Archiv/201303-Eliquis.pdf. Accessed June 5th 2018.
Drug Commission of the Germal Medical Association. https://www.akdae.de/Arzneimitteltherapie/NA/Archiv/2011030-Pradaxa.pdf. Accessed June 5th 2018.
Drug Commission of the Germal Medical Association. https://www.akdae.de/Arzneimitteltherapie/NA/Archiv/201310-Xarelto.pdf. Accessed June 5th 2018.
Drug Commission of the Germal Medical Association. https://www.akdae.de/Arzneimitteltherapie/NA/Archiv/201504-Lixiana-DVT.pdf. Accessed June 5th 2018.
Laux G, Koerner T, Rosemann T, Beyer M, Gilbert K, Szecsenyi J. The CONTENT project: a problem-oriented, episode-based electronic patient record in primary care. Informatics in primary care. 2005;13:249–55.
Andreotti F, Rocca B, Husted S, Aijan RA, ten Berg J, Cattaneo M, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on thrombosis. Eur Heart J. 2015;36:3238–49.
Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;130:138–46.
Hobbs FR, Taylor CJ, Jan Geersing G, Rutten FH, Brouwer JR. European primary care cardiovascular society Swg. European primary care cardiovascular society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol. 2016;23:460–73.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.
Last JM, Adelaide MB. The iceberg “completing the clinical picture” in general practice. Lancet. 1963;282:28–31.